Skip to content

I-ASV in Cardiac Surgery

POStoperative INTELLiVENT-adaptive Support VEntilation in Cardiac Surgery Patients II (POSITiVE II) - a Randomized Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06178510
Acronym
POSITiVE II
Enrollment
328
Registered
2023-12-21
Start date
2024-05-31
Completion date
2025-12-31
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator Lung

Keywords

Adaptative Support Ventilation, INTELLiVENT, Cardiac Surgery, Workload

Brief summary

'POStoperative INTELLiVENT-adaptive support VEntilation in cardiac surgery patients II (POSITiVE II) is an investigator-initiated, international, multicenter, parallel, randomized clinical trial in patients after cardiac surgery.

Detailed description

To compare INTELLiVENT-ASV with conventional ventilation with respect to (i.) quality of ventilation; and (ii.) ICU nursing staff workload in an international cohort of participants receiving postoperative ventilation after cardiac surgery. This study will also determine the effects of INTELLiVENT-ASV on clinical outcomes, including (iii.) duration of postoperative ventilation and (iv.) length of stay in ICU.

Interventions

DEVICEINTELLiVENT-ASV.

INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs

Sponsors

University Hospital Dubrava
CollaboratorOTHER
Università degli Studi dell'Insubria
CollaboratorUNKNOWN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
University of Zurich
CollaboratorOTHER
Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

* 1\. aged \> 18 years of age; * 2\. scheduled for elective cardiac surgery; and * 3\. expected to receive postoperative ventilation in the ICU for \> 2 hours.

Exclusion criteria

1. any emergency or semi-elective surgery (precluding informed written consent); 2. any surgery other than CABG, valve replacement or repair, or a combination (i.e., patients planned for surgery for congenital heart disease, or scheduled for heart transplantation are excluded); 3. enrolled in another interventional trail; 4. no written informed consent obtained; 5. history of recent pneumectomy or lobectomy; 6. history of COPD with oxygen at home; 7. body mass index \> 35; 8. preoperative forced expiratory volume in the first second (FeV1)/forced vital capacity (VC) \< 50% (if available); 9. preoperative arterial oxygen partial pressure (PaO2) \< 60 mm Hg (at room air); 10. preoperative arterial carbon dioxide partial pressure (PaCO2) \> 50 mm Hg; 11. preoperative left ventricular ejection fraction \< 30% (if available); 12. preoperative systolic pulmonary artery pressure \> 60 mm Hg (if available); 13. preoperative left ventricular mechanical support, e.g., Impella®; or 14. preoperative use of veno-venous or veno-arterial extracorporeal support At the end of surgery, patients are additionally excluded if a patient: 15. cannot be weaned from the extracorporeal support; or 16. unexpectedly needs implementation of an assist device

Design outcomes

Primary

MeasureTime frameDescription
Quality of ventilationDuring the first 2 hours, since admission on the ICU with the start of the intervention ventilation mode.The primary outcome is quality of ventilation, which is the proportion of time spent in three predefined and previously used zones of ventilation in the first 2 hours of postoperative ventilation. * An optimal zone = Tidal volume (TV) = 4-8 ml/kg of the predicted body weight (PBW) with an EtCO2 = 30-45mmHg, a plateau pressure = \<31cmH2O and SpO2 = 93-98%. * An acceptable zone = TV = 8-12 ml/kg of PBW with an EtCO2 = 25-30 or 45-50mmHg, a plateau pressure = 31-35 cmH2O and SpO2 = 85-93% or \>98%. * An unacceptable zone = TV \>12 ml/kg of PBW or an EtCO2 = \<25 or \>50mmHg, plateau pressure \>35 cmH2O or SpO2 = \<85%.

Secondary

MeasureTime frameDescription
Duration of postoperative ventilation8 hours or until extubationThe time from admission on the ICU until extubation.
Patient-ventilator asynchronyUp to 6 hours of mechanical ventilation timepatient-ventilator asynchrony requiring deepening of sedation and/or administration of muscle relaxants
Proportion of breath spent in zones of ventilationUp to 6 hours of mechanical ventilation timeProportion of breaths spent in predefined and previously used zones of ventilation in the first 6 hours of postoperative ventilation. * An optimal zone = Tidal volume (TV) = 4-8 ml/kg of the predicted body weight (PBW) with an EtCO2 = 30-45mmHg, a plateau pressure = \<31cmH2O and SpO2 = 93-98%. * An acceptable zone = TV = 8-12 ml/kg of PBW with an EtCO2 = 25-30 or 45-50mmHg, a plateau pressure = 31-35 cmH2O and SpO2 = 85-93% or \>98%. * An unacceptable zone = TV \>12 ml/kg of PBW or an EtCO2 = \<25 or \>50mmHg, plateau pressure \>35 cmH2O or SpO2 = \<85%.
ICU nursing staff workload24 hoursICU nursing staff workload, which is captured by the ventilator software collecting data on alarms (number of alarms, types of alarm, duration of alarm, responses to alarm, alarm settings and adjustments, breath-by-breath alarm data, and any manual intervention at the ventilator) during postoperative care in the ICU
Hospital length of stayFrom date of hospital admission until the date of hospital discharge, assessed up to 30 daysLength of stay in hospital
Mortality28-dayMortality in ICU or hospital
ICU length of stayFrom date of ICU admission until the date of ICU discharge, assessed up to 30 daysLength of stay in the ICU

Countries

Austria

Contacts

Primary ContactEdda Tschernko, MD
edda.tschernko@meduniwien.ac.at00 43 1 40400 41090
Backup ContactMartin H. Bernardi, MD
martin.bernardi@meduniwien.ac.at00 43 1 40400 41090

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026